Abstract
Whither oncolytic viruses? From the peak of their popularity in the early 2000s, when the ONYX-015 adenovirus had just entered the clinic, and then again in 2015 when the Food and Drug Administration-approved talimogene laherparepvec (also known as OncoVEXGM-CSF), which briefly revived interest, oncolytic viruses (OVs) have mostly fallen out of favor despite the many pharmaceutical companies with OVs in development.This commentary enumerates and addresses the core conceptions, perceptions, and misconceptions that characterize the current ‘trough of disillusionment’ in which the field of anticancer virotherapy finds itself and suggests reasons for optimism.
Subject
Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy
Reference16 articles.
1. Time to Debunk an urban myth? the ‘Abscopal effect’ with radiation and anti-PD-1;Seiwert;J Clin Oncol,2021
2. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
3. Abstract P3-07-20: treatment of 4T1 breast cancer with liposome-encapsulated adapt-001, a TGF-beta trap encoded oncolytic adenovirus currently in a phase 1/2 anticancer trial;Reid;Cancer Res,2023
4. Dummer R , Gyorki D , Hyngstrom J , et al . Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (TX) plus surgery vs immediate surgery in patients (Pts) with resectable stage IIIB-Ivm1A melanoma (MEL). Annals of Oncology 2022;33. doi:10.1016/j.annonc.2022.08.037
5. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (Dl1520): phase II viral, immunologic, and clinical endpoints;Reid;Cancer Res,2002
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献